Medical Foods for Inborn Errors of Metabolism: History, Current Status, and Critical Need

Author:

Berry Susan A.1,Brown Christine S.2,Greene Carol3,Camp Kathryn M.4,McDonough Stephen56,Bocchini Joseph A.78,

Affiliation:

1. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota;

2. National Phenylketonuria Alliance Inc, Eau Claire, Wisconsin;

3. Department of Pediatrics, University of Maryland, Baltimore, Maryland;

4. Office of Dietary Supplements, National Institutes of Health, Silver Springs, Maryland;

5. Follow-up and Treatment Workgroup,

6. Independent Doctors, Bismarck, North Dakota; and

7. Advisory Committee on Heritable Disorders in Newborns and Children, Health Resources and Services Administration, Rockville, Maryland

8. Department of Pediatrics, Louisiana State University, Shreveport, Louisiana

Abstract

Successful intervention for inborn errors of metabolism (IEMs) is a triumph of modern medicine. For many of these conditions, medical foods are the cornerstone of therapy and the only effective interventions preventing disability or death. Medical foods are designed for patients with limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foods or nutrients, whereby dietary management cannot be achieved by modification of the normal diet alone. In the United States today, access to medical foods is not ensured for many individuals who are affected despite their proven efficacy in the treatment of IEMs, their universal use as the mainstay of IEM management, the endorsement of their use by professional medical organizations, and the obvious desire of families for effective care. Medical foods are not sufficiently covered by many health insurance plans in the United States and, without insurance coverage, many families cannot afford their high cost. In this review, we outline the history of medical foods, define their medical necessity, discuss the barriers to access and reimbursement resulting from the regulatory status of medical foods, and summarize previous efforts to improve access. The Advisory Committee on Heritable Disorders in Newborns and Children asserts that it is time to provide stable and affordable access to the effective management required for optimal outcomes through the life span of patients affected with IEMs. Medical foods as defined by the US Food and Drug Administration should be covered as required medical benefits for persons of all ages diagnosed with an IEM.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology, and Child Health

Reference39 articles.

1. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants;Guthrie;Pediatrics,1963

2. Regulation of medical foods;Fed Regist,1996

3. US Food and Drug Administration. Medical foods guidance documents & regulatory information. Available at: https://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/medicalfoods/default.htm. Accessed May 1, 2017

4. Neurological outcome in adult patients with early-treated phenylketonuria;Pietz;Eur J Pediatr,1998

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3